Note*: This report requires 7-10 business days to complete.
DelveInsight’s Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Myelodysplastic Syndrome forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Myelodysplastic Syndrome till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Myelodysplastic Syndrome market.
• Identifying patient populations in the global “Myelodysplastic Syndrome market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Myelodysplastic Syndrome in each of the markets covered.
• To understand the future market competition in the global Myelodysplastic Syndrome market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Myelodysplastic Syndrome for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
'
Table of Contents
• Myelodysplastic Syndrome overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Myelodysplastic Syndrome Market
• Global Epidemiology of Myelodysplastic Syndrome Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Myelodysplastic Syndrome Drug Sales (USD Millions)-2023
• Table 6: Global Epidemiology of Myelodysplastic Syndrome (2013-2023)
• Table 7: Myelodysplastic Syndrome Global Market (USD Millions), (2013-2015)
• Table 8: Myelodysplastic Syndrome Global Market (USD Millions), (2016-2023)
• Table 9: Myelodysplastic Syndrome US Market (USD Millions), (2013-2015)
• Table 10: Myelodysplastic Syndrome US Market (USD Millions), (2016-2023)
• Table 11: Myelodysplastic Syndrome Germany Market (USD Millions), (2013-2015)
• Table 12: Myelodysplastic Syndrome Germany Market (USD Millions), (2016-2023)
• Table 13: Myelodysplastic Syndrome United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Myelodysplastic Syndrome United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Myelodysplastic Syndrome France Market (USD Millions), (2013-2015)
• Table 16: Myelodysplastic Syndrome France Market (USD Millions), (2016-2023)
• Table 17: Myelodysplastic Syndrome Italy Market (USD Millions), (2013-2015)
• Table 18: Myelodysplastic Syndrome Italy Market (USD Millions), (2016-2023)
• Table 19: Myelodysplastic Syndrome Spain Market (USD Millions), (2013-2015)
• Table 20: Myelodysplastic Syndrome Spain Market (USD Millions), (2016-2023)
• Table 21: Myelodysplastic Syndrome Japan Market (USD Millions), (2013-2015)
• Table 22: Myelodysplastic Syndrome Japan Market (USD Millions), (2016-2023)
• Table 23: Myelodysplastic Syndrome ROW Market (USD Millions), (2013-2015)
• Table 24: Myelodysplastic Syndrome ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Myelodysplastic Syndrome Drug Sales (USD Millions)-2023
• Figure 2: Global Epidemiology of Myelodysplastic Syndrome (2013-2023)
• Figure 3: Myelodysplastic Syndrome Global Market (USD Millions), (2013-2015)
• Figure 4: Myelodysplastic Syndrome Global Market (USD Millions), (2016-2023)
• Figure 5: Myelodysplastic Syndrome US Market (USD Millions), (2013-2015)
• Figure 6: Myelodysplastic Syndrome US Market (USD Millions), (2016-2023)
• Figure 7: Myelodysplastic Syndrome Germany Market (USD Millions), (2013-2015)
• Figure 8: Myelodysplastic Syndrome Germany Market (USD Millions), (2016-2023)
• Figure 9: Myelodysplastic Syndrome United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Myelodysplastic Syndrome United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Myelodysplastic Syndrome France Market (USD Millions), (2013-2015)
• Figure 12: Myelodysplastic Syndrome France Market (USD Millions), (2016-2023)
• Figure 13: Myelodysplastic Syndrome Italy Market (USD Millions), (2013-2015)
• Figure 14: Myelodysplastic Syndrome Italy Market (USD Millions), (2016-2023)
• Figure 15: Myelodysplastic Syndrome Spain Market (USD Millions), (2013-2015)
• Figure 16: Myelodysplastic Syndrome Spain Market (USD Millions), (2016-2023)
• Figure 17: Myelodysplastic Syndrome Japan Market (USD Millions), (2013-2015)
• Figure 18: Myelodysplastic Syndrome Japan Market (USD Millions), (2015-2023)
• Figure 19: Myelodysplastic Syndrome ROW Market (USD Millions), (2013-2015)
• Figure 20: Myelodysplastic Syndrome ROW Market (USD Millions), (2016-2023)
• Celgene Corporation
• Novartis AG
• Sanofi
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• Onconova Therapeutics Inc.
• Groupe Francophone des Myelodysplasies
• Amgen Inc.
• Eisai Co. Ltd.
